These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26502989)

  • 1. Kidney cancer: TKIs associated with stroke risk.
    Fenner A
    Nat Rev Urol; 2015 Nov; 12(11):597. PubMed ID: 26502989
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
    Jang S; Zheng C; Tsai HT; Fu AZ; Barac A; Atkins MB; Freedman AN; Minasian L; Potosky AL
    Cancer; 2016 Jan; 122(1):124-30. PubMed ID: 26439451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T
    Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
    [No Abstract]   [Full Text] [Related]  

  • 4. New therapeutic options for renal cell carcinoma.
    Stadler W
    Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
    [No Abstract]   [Full Text] [Related]  

  • 5. Maturing of renal cancer therapeutics.
    Stadler WM
    J Clin Oncol; 2014 Mar; 32(8):722-4. PubMed ID: 24516015
    [No Abstract]   [Full Text] [Related]  

  • 6. Kidney cancer: Temsirolimus fails to expand its role in patients with mRCC.
    Payton S
    Nat Rev Urol; 2014 Jan; 11(1):2. PubMed ID: 24346004
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.
    Westgeest HM; van Erp NP; Honeywell RJ; Hoekstra R; Peters GJ; Verheul HM
    J Clin Oncol; 2013 Feb; 31(6):e83-6. PubMed ID: 23182994
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted therapies: Juggling combinations--not the way forward.
    Hutchinson L
    Nat Rev Clin Oncol; 2014 Feb; 11(2):64. PubMed ID: 24343669
    [No Abstract]   [Full Text] [Related]  

  • 9. [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
    Staehler M; Haseke N; Schöppler G; Stadler T; Heinemann G; Stief CG
    Urologe A; 2006 Oct; 45(10):1333-42; quiz 1343. PubMed ID: 17021905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney cancer: SWITCHing inconsequential.
    Thoma C
    Nat Rev Urol; 2015 Jun; 12(6):305. PubMed ID: 25986758
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of vascular endothelial growth factor and multikinase inhibitor side effects.
    Wood LS
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():13-8. PubMed ID: 19948455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing side effects of angiogenesis inhibitors in renal cell carcinoma.
    Grünwald V; Heinzer H; Fiedler W
    Onkologie; 2007 Oct; 30(10):519-24. PubMed ID: 17890892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract]   [Full Text] [Related]  

  • 14. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
    Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From theoretical synergy to clinical supra-additive toxicity.
    Soria JC; Massard C; Izzedine H
    J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib-Sunitinib Sequence: The Jury Is Out.
    Albiges L; Escudier B
    Eur Urol; 2015 Nov; 68(5):848-9. PubMed ID: 26184972
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
    Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
    Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the role of novel agents in the treatment of renal cell carcinoma.
    Maluf FC; Fernandes Gdos S; Kann AG; Aguilar-Ponce JL; de la Garza J; Buzaid AC
    Cancer Treat Rev; 2008 Dec; 34(8):750-60. PubMed ID: 18801619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
    Schmidinger M; Zielinski CC; Vogl UM; Bojic A; Bojic M; Schukro C; Ruhsam M; Hejna M; Schmidinger H
    J Clin Oncol; 2008 Nov; 26(32):5204-12. PubMed ID: 18838713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.